DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/0c91ba/oncology_market_in) has announced the addition of the "Oncology Market in China to 2017 - Better Access to Cancer Therapies for the Rising Cancer Population through Healthcare Reforms Drives the Market" report to their offering.
Oncology Market in China to 2017 - Better Access to Cancer Therapies for the Rising Cancer Population through Healthcare Reforms Drives the Market, which provides insights into oncology sales and price forecasts in China until 2017. The report also examines Chinese oncology treatment usage patterns. In addition, the report also includes insights into the oncology Research and Development (R&D) pipeline. The report provides an in-depth analysis of the top five oncology therapeutic indications, which are breast cancer, colorectal cancer, prostate cancer, lung cancer and Non-Hodgkins Lymphoma (NHL).
It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.
The Oncology Market in China is Expected to Witness a High Growth Rate Driven by Growing Cancer Prevalence and Better Drug Access
The oncology market in China is estimated to reach $2.2 billion in 2017 from $830m in 2009, indicating a CAGR (Compound Annual Growth Rate) of 12.9% between 2009 and 2017. The major drivers of this growth will be the increasing prevalence population for major cancer indications, increased use of chemotherapy drugs, increasing rate of urbanization and high unmet need in terms of safer and more efficacious medicines.
However, the dominance of generics in the local oncology market, the low level of reimbursements for Western, branded pharmaceutical drugs as well as the nuisance of counterfeit drugs are expected to be some of the biggest challenges facing big pharmaceutical companies attempting to establish themselves in the Chinese oncology market.
The Top Five Companies in Chinas Oncology Market Account for Less than 30% of Market Share
The competition in the cancer therapeutics market in China is largely dominated by the big pharmaceutical companies of the US and Europe. However, the market is highly fragmented, with the top five players occupying only 29% of the entire market. There is only one Chinese company, Simcere, which found a place in the top five players, with 5% of the market share, third highest after Roche/Genentech and AstraZeneca. This represents substantial scope for Mergers and Acquisitions (M&A) to improve the competitive positions of the leading players in the market.
However, a noteworthy aspect of the competitive landscape is the next five major players in the market, which includes three Chinese companies (Sichuan Jiufeng, Jiangsu LYG Hengrui Pharma and Shanghai Jinhe Biotechnology Company Ltd.) and a Japanese company (Symbio Pharmaceuticals), as well as European company Sanofi-aventis.
Going forward, the competition in the branded oncology drugs market is expected to increase as the Chinese pharmaceutical market opens up to patented drugs. In addition, the growth in the overall oncology market is also expected to attract other major pharmaceutical companies to China.
Scope:
- Data and analysis on the oncology market in the China
- Annualized market data for the oncology market from 2002 to 2009, with forecasts to 2017.
- Market data on the therapeutic landscape which covers lung cancer, breast cancer, colorectal cancer, non-hodgkins lymphoma and prostate cancer, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population and treated population.
- Key drivers and restraints that have had a significant impact on the market and on each indication.
- The regulatory landscape which covers major regulatory bodies in China, IPR protection, key regulations for conducting oncology research, key government initiatives and pricing and reimbursement scenario
- The competitive landscape of the Chinese oncology market which includes companies such as Roche/Genentech, AstraZeneca, Simcere, Merck and GlaxoSmithKline
- Key M&A activities and Licensing Agreements that took place from 2004 to 2010 in the Chinese oncology market.
Reasons to buy:
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading countries and therapeutic segments poised for strong growth.
- Device a more tailored country strategy through the understanding of key drivers and barriers of the regions pharmaceutical market.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.
Key Topics Covered:
1 Table of Contents
2 Oncology in China Introduction
3 Oncology in China Market Characterization
4 Oncology in China: Therapeutic Landscape
5 Oncology in China Regulatory Landscape
6 Oncology in China Pipeline Analysis
7 Oncology in China Competitive Landscape
8 Oncology in China Deals Landscape
9 Appendix
For more information visit http://www.researchandmarkets.com/research/0c91ba/oncology_market_in